Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.

Min Hwan KimGun Min KimJee Hung KimJee Ye KimHyung Seok ParkSeho ParkYoung Up ChoByeong Woo ParkSeung Il KimJoo Hyuk Sohn

Published in: Breast cancer research and treatment (2019)

Intermediate HER2 expression is an independent predictor of poor prognosis in both ER+ EBC and MBC patients aged ≥ 55 years. The clinical efficacy of new HER2-targeting antibody-drug conjugates needs to be validated in this high-risk subset of ER+ breast cancer patients.

Keyphrases

poor prognosis
long non coding rna
estrogen receptor
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
positive breast cancer
patient reported
endoplasmic reticulum